Wikipedia

Health effects of snus

The chemical constituents of different types of snus vary, and population-level studies suggest that the disease risks vary as well.[1] Using snus is harmful to health, although much less than smoking tobacco.[2]

Snus and cancer: conflicting studies

edit

A study of close to 10,000 Swedish, male construction workers published in the International Journal of Cancer in 2008 found a statistically significant increase in the incidence of the combined category of oral and pharyngeal cancer among daily users of snus.[3] Other studies and opinion pieces in renowned journals, such as the British Medical Journal and The Lancet,[4][5] do not confirm any correlation between snus usage and oral cancer, but one study suggests a probable increased risk of pancreatic cancer as a result of snus use.[6] A pooled analysis of nine prospective studies involving more than 400,000 men and published in the International Journal of Cancer in 2017 found that use of snus was not associated with a greater risk for pancreatic cancer.[7]

Regulatory actions: EU's ban on snus

edit
 
Tobacco shop in Neuchâtel, Switzerland in 2020: Advertising for tobacco (here for snus Epok from British American Tobacco) is authorized inside the shop.

The European Union banned the sale of snus in 1992, after a 1985 World Health Organization (WHO) study concluded that "oral use of snuffs of the types used in North America and western Europe is carcinogenic to humans",[8] but a WHO committee on tobacco has also acknowledged the evidence is inconclusive regarding health consequences for snus consumers.[9] Only Sweden and European Free Trade Association (EFTA)-member Norway are exempt from this ban. A popular movement during the run-up to the 1994 referendum for Sweden's EU membership made exemption from the EU sale ban of snus a condition of the membership treaty.

Snus as a smoking substitute: arguments and repercussions

edit

Recent actions by many European governments to limit the use of cigarettes has led to calls to lift the ban on snus, as it is generally considered to be less harmful than cigarette smoke, both to the user [10] and to others.

Regulatory changes and controversies in snus labeling

edit

Snus manufacturer Swedish Match filed a modified risk tobacco product (MRTP) application with the U.S. Food and Drug Administration (FDA) Center for Tobacco Products to modify the warning label requirements by:[11]

  1. removing the current warnings, "This product can cause mouth cancer" and "This product can cause gum disease and tooth loss."
  2. replacing the current warning, "This product is not a safe alternative to cigarettes”, with "No tobacco product is safe, but this product presents substantially lower risks to health than cigarettes."
  3. retaining the current warning, "Smokeless tobacco is addictive."

The FDA's Tobacco Products Scientific Advisory Committee voted against the request in April 2015 but Swedish Match is continuing their efforts for this change.[12]

R. J. Reynolds has also filed an MRTP application with the FDA for its Camel snus product. As of May 2018, the FDA has yet to issue a ruling.[13]

Medical journal The Lancet [14] published a major study, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016", in November 2017. The scientific conclusions with regards to snus was the following. "There is sufficient evidence that chewing tobacco and other products of similar toxicity cause excess risk of oral and oesophageal cancer while, at this time, existing evidence does not support attributing burden to snus or similar smokeless tobacco products." ...while for snus or snuff we did not find sufficient evidence of a RR (relative risk) greater than one for any health outcome." A relative risk [RR] of 1.0, means you are average — [there is no difference in risk between the control and experimental groups]".[15]

Snus in pregnancy and availability in the United States

edit

During pregnancy[16] and breastfeeding,[17] mothers are advised not to use any products containing nicotine,[18] which harms the fetus.[19]

Scandinavian snus is regularly available, refrigerated, in the United States at smokeshops and select gas stations, especially in major cities. The considerably different, sweetened American snus is more commonly found at convenience stores, in multiple brands produced by US-based cigarette companies. Neither product category has made much of an inroad into the market-share held by the dipping tobacco products more common in that country.

Effects of snus on oral microbiota

edit

Snus has been scrutinized for its potential effect on oral microbiota.[20] Oral microbiota, consisting of microorganisms in the oral cavity, plays a crucial role in maintaining oral health. Imbalances in oral microbiota can lead to oral health issues, with various factors, including tobacco use, influencing this balance.

While research has indicated that smoking significantly alters oral microbiota,[21] studies on the effects of snus are limited. Preliminary studies suggest that snus may affect the composition and diversity of oral microbiota.[22] Specifically, one study identified differences in the abundance of certain bacterial species between snus users and non-users.

Despite snus usage being associated with conditions like gum recession and tooth discoloration, the connection to severe oral health problems such as periodontal disease and oral cancer remains inconclusive. Nonetheless, snus contains harmful chemicals,[23] including nicotine, which could negatively affect oral health. More research is needed to fully understand snus's effects on oral microbiota and its implications on oral health.

Snus sensations: the role of nicotine and additives

edit

The burning sensation often experienced with snus is caused by the nicotine itself (similar to the tingle of nicotine gum) and some food additives such as sodium carbonate (E500). Sodium carbonate is a food additive used to increase the pH of the tobacco (reduce the acidity). This increases the bioavailability of the nicotine, meaning more is available for absorption. Mucous membranes readily absorb free nicotine. Some flavorings (mints in particular) are astringent and may increase the tingling or burning sensation.

Public health debate

edit

Divergent views on harm reduction

edit

There is some debate among public health researchers over the use of "safer" tobacco or nicotine delivery systems, generally dividing along two lines of thought. Some (primarily in the European Union and Canada) believe in "tobacco harm reduction", with the general belief that while it should remain a goal to reduce addiction to nicotine in the population as a whole, the reduction of harm to the health of those who choose to use nicotine is more pragmatic than the desire to reduce overall nicotine addiction. In other words, people using more harmful forms of tobacco (e.g., cigarettes) should be encouraged to switch to less harmful products (e.g., snus). The other school of thought is that no tobacco product should be promoted, and that attention should be placed instead on getting users to switch to nicotine replacement therapy or quit altogether.

Snus as a harm reduction tool: proponents' perspective

edit

One proponent of using snus for harm reduction is Karl Fagerström, who has a PhD in psychology and is researcher in smoking cessation in Sweden. Some research available today shows snus use reduces or eliminates the risk of cancers associated with the use of other tobacco products, such as chewing tobacco (the type primarily used in the US and Canada, created in a process similar to cigarette tobacco) and cigarettes.[24] The widespread use of snus by Swedish men (estimated at 30% of Swedish male ex-smokers), displacing tobacco smoking and other varieties of snuff, is thought to be responsible for the incidence of tobacco-related mortality in men being significantly lower in Sweden than any other European country [citation needed]. In contrast, since women traditionally are less likely to use snus, their rate of tobacco-related deaths in Sweden can be compared to that of other European countries.

Snus may be less harmful than other tobacco products (see above). According to Kenneth Warner, director of the University of Michigan Tobacco Research Network, "The Swedish government has studied this stuff to death and, to date, there is no compelling evidence that it has any adverse health consequences. … Whatever they eventually find out, it is dramatically less dangerous than smoking."[25]

Snus in the context of tobacco harm reduction

edit

A 2014 report commissioned by Public Health England on another avenue for tobacco harm reduction, electronic cigarettes, examined the case of snus as "a unique natural experiment in the impact of a socially accepted, non-medical, affordable and easily accessible reduced harm product on the prevalence of tobacco smoking". They concluded that "Although controversial, the Swedish natural experiment demonstrates that despite dual use and primary uptake of the reduced-harm product by young people, availability of reduced-harm alternatives for tobacco smokers can have a beneficial effect. While snus is not likely to become a legal or indeed politically viable option in the UK, this data proves the concept that harm reduction strategies can contribute to significant reductions in smoking prevalence."[26]

Debates on snus use and life expectancy

edit

Ongoing discussion and debates among primary scientific researchers of the effects of snus use on life expectancy appear to indicate a significant increase in life expectancy among persons who previously smoked tobacco and switch to snus, depending on the age of the persons who switch, even when it is assumed that 100% of the risk of cardiovascular diseases among smokers transfers to snus users. This study determined that "for net harm to occur, 14–25 ex-smokers would have to start using snus to offset the health gain from every smoker who switched to snus."[27] It is also noted, in the correspondence seen in the previous citation,[28][29] that concerns about the effect of marketing by the tobacco industry, as influenced by the results of these scientific studies, is of primary concern to many researchers in the field, including the risk of emboldening the industry to attempt to increase snus sales among young people and promote dual-use of snus and smoked tobacco, and the use of medical nicotine, rather than snus, can better target at-risk populations, given better access and pricing.

Limitations of nicotine replacement therapy and the potential role of snus

edit

However, a growing consensus among researchers of smoking cessation have found nicotine replacement therapy (NRT) products to have limited effectiveness because tobacco users may be seeking the combination of MAO inhibitors (which are found in tobacco) and nicotine, or that NRT products do not deliver sufficient quantities of nicotine. MAO inhibitors in tobacco act to amplify the rewarding effects of nicotine, but may also act as a form of self-medication for people with depression. This could explain the association between mental illness and smoking, but a confounding variable is that chronic nicotine administration itself has been shown to desensitize nicotine receptors over time and lead to antidepressant effects.[30] Smoking cessation itself is strongly associated with reduced depression, anxiety, and stress and improved positive mood and quality of life compared with continuing to smoke.[31] It has been hypothesized that snus' success when compared with conventional NRT as a cigarette substitute could be attributed to its MAO inhibiting properties. However, studies seem to suggest that for MAO inhibition, tobacco has to be pyrolysized (i.e., ignited as in cigarettes, cigars, and pipes). The competing theory is that the success of snus as a smoking alternative is due to its ability to deliver nicotine similar to that acquired through cigarettes, and twice as high as that acquired through NRT.[32] Furthermore, the use of snus, similar to cigarettes, offers a choice of brand, aesthetic rituals of use, and tastes of tobacco and thus has sensory effects that NRT products perhaps lack.

Snus vs conventional NRT: success rates in smoking cessation

edit

The use of daily snus for smoking cessation has had a 54% success rate for complete abstinence, and a 60% success rate for great reduction in cigarette consumption.[33]

The debate over nitrosamine levels in snus

edit

Opponents of snus sales maintain, nevertheless, that even the low nitrosamine levels in snus cannot be completely risk-free, but snus proponents point out that, inasmuch as snus is used as a substitute for smoking or a means to quit smoking, the net overall effect is positive, similar to the effect of nicotine patches.[34]

Snus, second-hand smoke, and the harm reduction perspective

edit

In addition, this eliminates any exposure to second-hand smoke, further reducing possible harm to other non-tobacco users. This is seen by public health advocates who believe in "harm reduction" as a reason for recommending snus, as well as other NRTs, rather than continued use of methods of tobacco consumption that result in second-hand smoke.

This does not, however, eliminate any harm to health caused by the nicotine itself. Current research focuses on possible long-term side effects of nicotine on blood pressure, hypertension, and possible risk of pancreatic cancer due to tobacco-specific nitrosamines (TSNAs). TSNAs are the only component of tobacco shown to induce pancreatic cancer in laboratory animals.[35] Nicotine may also exacerbate pancreatic illness, because nicotine stimulates the gastrointestinal tract's production of cholecystokinin, which stimulates pancreatic growth and may be implicated in pancreatic cancer. Thus far, the evidence specifically implicating snus in pancreatic cancer is only suggestive.[36][37] Notably, the probability of developing pancreatic cancer from cigarettes is higher than the suggested chance of developing pancreatic cancer from snus.[38][39]

The effect of Swedish snus on blood pressure has been studied at Umeå University in a randomly selected population sample of 4,305 Swedish men between the ages of 25 and 74. In the study, published in November 2008, the researchers found no elevation of blood pressure in snus users who had never been smokers compared to tobacco nonusers.[40]

References

edit
  1. ^ Siddiqi, Kamran; Shah, Sarwat; Abbas, Syed Muslim; Vidyasagaran, Aishwarya; Jawad, Mohammed; Dogar, Omara; Sheikh, Aziz (2015-08-17). "Global burden of disease due to smokeless tobacco consumption in adults: analysis of data from 113 countries". BMC Medicine. 13: 194. doi:10.1186/s12916-015-0424-2. ISSN 1741-7015. PMC 4538761. PMID 26278072.
  2. ^ Lee, Peter N. (2013-12-06). "Epidemiological evidence relating snus to health – an updated review based on recent publications". Harm Reduction Journal. 10 (1): 36. doi:10.1186/1477-7517-10-36. ISSN 1477-7517. PMC 4029226. PMID 24314326.
  3. ^ Roosaar, Ann; Johansson, Anna L. V.; Sandborgh-Englund, Gunilla; Axéll, Tony; Nyrén, Olof (2008). "Cancer and mortality among users and nonusers of snus". International Journal of Cancer. 123 (1): 168–73. doi:10.1002/ijc.23469. PMID 18412245. S2CID 6667256.
  4. ^ MacAra, A. W. (2008). "Should doctors advocate snus and other nicotine replacements? No". BMJ. 336 (7640): 359. doi:10.1136/bmj.39479.491319.AD. PMC 2244771. PMID 18276711.
  5. ^ Rodu, Brad (2007). "Snus and the risk of cancer of the mouth, lung, and pancreas". The Lancet. 370 (9594): 1207–8, author reply 1208. doi:10.1016/S0140-6736(07)61533-5. PMID 17920914. S2CID 5746881.
  6. ^ Bertuccio, P.; La Vecchia, C.; Silverman, D. T.; Petersen, G. M.; Bracci, P. M.; Negri, E.; Li, D.; Risch, H. A.; Olson, S. H.; Gallinger, S.; Miller, A. B.; Bueno-De-Mesquita, H. B.; Talamini, R.; Polesel, J.; Ghadirian, P.; Baghurst, P. A.; Zatonski, W.; Fontham, E. T.; Bamlet, W. R.; Holly, E. A.; Lucenteforte, E.; Hassan, M.; Yu, H.; Kurtz, R. C.; Cotterchio, M.; Su, J.; Maisonneuve, P.; Duell, E. J.; Bosetti, C.; Boffetta, P. (2011). "Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: An analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4)". Annals of Oncology. 22 (6): 1420–6. doi:10.1093/annonc/mdq613. PMC 3139985. PMID 21245160.
  7. ^ Araghi, Marzieh; Rosaria Galanti, Maria; Lundberg, Michael; Lager, Anton; Engström, Gunnar; Alfredsson, Lars; Knutsson, Anders; Norberg, Margareta; Sund, Malin; Wennberg, Patrik; Trolle Lagerros, Ylva; Bellocco, Rino; Pedersen, Nancy L.; Östergren, Per-Olof; Magnusson, Cecilia (2017). "Use of moist oral snuff (snus) and pancreatic cancer: Pooled analysis of nine prospective observational studies". International Journal of Cancer. 141 (4): 687–693. doi:10.1002/ijc.30773. PMID 28486772.
  8. ^ "Tobacco habits other than smoking; betel-quid and areca-nut chewing; and some related nitrosamines. IARC Working Group. Lyon, 23-30 October 1984" (PDF). IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. 37: 1–268. 1985. PMID 3866741. Archived (PDF) from the original on 21 December 2014. Retrieved 17 February 2015.
  9. ^ Isabel Conway (21 April 2009). "Snuff is not to be sniffed at". Irish Times. Archived from the original on 16 October 2012. Retrieved 9 May 2009.
  10. ^ Levy, David T.; Mumford, Elizabeth A.; Cummings, K. Michael; Gilpin, Elizabeth A.; Giovino, Gary; Hyland, Andrew; Sweanor, David; Warner, Kenneth E. (2004). "The Relative Risks of a Low-Nitrosamine Smokeless Tobacco Product Compared with Smoking Cigarettes: Estimates of a Panel of Experts". Cancer Epidemiology, Biomarkers & Prevention. 13 (12): 2035–42. doi:10.1158/1055-9965.2035.13.12. PMID 15598758. S2CID 23560680. Archived from the original on 2013-02-23. Retrieved 2012-10-23.
  11. ^ "Swedish Match North America MRTP Applications". 27 August 2014. Archived from the original on 19 October 2014. Retrieved 24 October 2014.
  12. ^ "Modified Risk: Down But Not Out". Archived from the original on 2016-02-03. Retrieved 2016-01-28.
  13. ^ "R.J. Reynolds Tobacco Company Modified Risk Tobacco Product (MRTP) Applications". Tobacco Products. U.S. Food and Drug Administration. May 9, 2018. Archived from the original on 24 April 2018. Retrieved 11 May 2018.
  14. ^ Gakidou, Emmanuela; Afshin, Ashkan; Abajobir, Amanuel Alemu; Abate, Kalkidan Hassen; Abbafati, Cristiana; Abbas, Kaja M.; Abd-Allah, Foad; Abdulle, Abdishakur M.; Abera, Semaw Ferede; Aboyans, Victor; Abu-Raddad, Laith J.; Abu-Rmeileh, Niveen M. E.; Abyu, Gebre Yitayih; Adedeji, Isaac Akinkunmi; Adetokunboh, Olatunji; Afarideh, Mohsen; Agrawal, Anurag; Agrawal, Sutapa; Ahmadieh, Hamid; Ahmed, Muktar Beshir; Aichour, Miloud Taki Eddine; Aichour, Amani Nidhal; Aichour, Ibtihel; Akinyemi, Rufus Olusola; Akseer, Nadia; Alahdab, Fares; Al-Aly, Ziyad; Alam, Khurshid; Alam, Noore; et al. (2017). "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016". The Lancet. 390 (10100): 1345–1422. doi:10.1016/S0140-6736(17)32366-8. PMC 5614451. PMID 28919119.
  15. ^ "understanding absolute and relative-risk in medical risk analysis and putting this in context". www.Nutridesk.com.au. Archived from the original on 9 January 2018. Retrieved 2 January 2018.
  16. ^ Mann, Denise. "Snuff Use During Pregnancy Is Harmful to Newborns". WebMD. Archived from the original on 2018-10-27. Retrieved 2018-06-06.
  17. ^ Centre of Excellence for Women's Health (September 2017), Women and Tobacco (PDF), archived (PDF) from the original on 2018-10-17, retrieved 2018-06-06, smokeless forms of tobacco such as snuff, chewing tobacco, and snus... it is best not to use tobacco while breastfeeding as nicotine passes to the baby through breast milk.
  18. ^ Bruin, Jennifer E.; Gerstein, Hertzel C.; Holloway, Alison C. (2010-04-02). "Long-Term Consequences of Fetal and Neonatal Nicotine Exposure: A Critical Review". Toxicological Sciences. 116 (2): 364–374. doi:10.1093/toxsci/kfq103. ISSN 1096-6080. PMC 2905398. PMID 20363831. Overall, the evidence provided in this review overwhelmingly indicates that nicotine should no longer be considered the safe component of cigarette smoke. In fact, many of the adverse postnatal health outcomes associated with maternal smoking during pregnancy may be attributable, at least in part, to nicotine alone.
  19. ^ England, Lucinda J.; Kim, Shin Y.; Tomar, Scott L.; Ray, Cecily S.; Gupta, Prakash C.; Eissenberg, Thomas; Cnattingius, Sven; Bernert, John T.; Tita, Alan Thevenet N.; Winn, Deborah M.; Djordjevic, Mirjana V.; Lambe, Mats; Stamilio, David; Chipato, Tsungai; Tolosa, Jorge E. (31 December 2010). "Non-cigarette tobacco use among women and adverse pregnancy outcomes". Acta Obstetricia et Gynecologica Scandinavica. 89 (4): 454–464. doi:10.3109/00016341003605719. ISSN 1600-0412. PMC 5881107. PMID 20225987. The use of any products containing nicotine likely will have adverse effects of fetal neurological development.
  20. ^ "Snus and Oral Microbiota Diversity". Snusline. July 2023.
  21. ^ Jia, Y. J.; Liao, Y.; He, Y. Q.; Zheng, M. Q.; Tong, X. T.; Xue, W. Q.; Zhang, J. B.; Yuan, L. L.; Zhang, W. L.; Jia, W. H. (18 May 2021). "Association Between Oral Microbiota and Cigarette Smoking in the Chinese Population". Frontiers in Cellular and Infection Microbiology. 11: 658203. doi:10.3389/fcimb.2021.658203. PMC 8195269. PMID 34123872.
  22. ^ Liu, M.; Jin, J.; Pan, H.; Feng, J.; Cerniglia, C. E.; Yang, M.; Chen, H. (15 October 2016). "Effect of smokeless tobacco products on human oral bacteria growth and viability". Anaerobe. 42: 152–161. doi:10.1016/j.anaerobe.2016.10.006. PMC 5693344. PMID 27756619.
  23. ^ "Snus Tobacco Health Risks". WebMD. 21 July 2016.
  24. ^ Foulds J, Ramstrom L, Burke M, Fagerström K (2003). "Effect of smokeless tobacco (snus) on smoking and public health in Sweden" (PDF). Tobacco Control. 12 (4): 349–359. doi:10.1136/tc.12.4.349. PMC 1747791. PMID 14660766. Archived from the original (PDF) on 2006-07-14. Retrieved 2006-07-14.
  25. ^ Rabinoff, Michael (2007). "Corporate Social Responsibility As A Tactic Used By Big Tobacco". Ending the Tobacco Holocaust. Elite Books. pp. 375–9. ISBN 978-1-60070-019-4.
  26. ^ Britton, John; Bogdanovica, Ilze (15 May 2014). "Electronic cigarettes – A report commissioned by Public Health England" (PDF). Public Health England. p. 11=12. Archived (PDF) from the original on 10 October 2015. Retrieved 24 August 2015.
  27. ^ Gartner, Coral E.; Hall, Wayne D.; Vos, Theo; Bertram, Melanie Y.; Wallace, Angela L.; Lim, Stephen S. (2007). "Assessment of Swedish snus for tobacco harm reduction: An epidemiological modelling study" (PDF). The Lancet. 369 (9578): 2010–4. doi:10.1016/S0140-6736(07)60677-1. PMID 17498798. S2CID 10758355.
  28. ^ McKee, Martin; Gilmore, Anna (2007). "Swedish snus for tobacco harm reduction". The Lancet. 370 (9594): 1206, author reply 1206–7. doi:10.1016/S0140-6736(07)61530-X. PMID 17920913. S2CID 1196126.
  29. ^ Lambe, Mats (2007). "Swedish snus for tobacco harm reduction". The Lancet. 370 (9594): 1206, author reply 1206–7. doi:10.1016/S0140-6736(07)61531-1. PMID 17920911. S2CID 35838314.
  30. ^ Mineur, Yann S.; Picciotto, Marina R. (2010). "Nicotine receptors and depression: Revisiting and revising the cholinergic hypothesis". Trends in Pharmacological Sciences. 31 (12): 580–6. doi:10.1016/j.tips.2010.09.004. PMC 2991594. PMID 20965579.
  31. ^ Taylor, G.; McNeill, A.; Girling, A.; Farley, A.; Lindson-Hawley, N.; Aveyard, P. (2014). "Change in mental health after smoking cessation: Systematic review and meta-analysis". BMJ. 348: g1151. doi:10.1136/bmj.g1151. PMC 3923980. PMID 24524926.
  32. ^ Foulds, J.; Ramstrom, L.; Burke, M.; Fagerström, K. (2003). "Effect of smokeless tobacco (snus) on smoking and public health in Sweden". Tobacco Control. 12 (4): 349–59. doi:10.1136/tc.12.4.349. PMC 1747791. PMID 14660766.
  33. ^ Lund, K. E.; McNeill, A.; Scheffels, J. (2010). "The use of snus for quitting smoking compared with medicinal products". Nicotine & Tobacco Research. 12 (8): 817–822. doi:10.1093/ntr/ntq105. PMC 2910876. PMID 20622023.
  34. ^ Furberg, H.; Lichtenstein, P.; Pedersen, N. L.; Bulik, C. M.; Lerman, C.; Sullivan, P. F. (2007). "Snus use and other correlates of smoking cessation in the Swedish Twin Registry". Psychological Medicine. 38 (9): 1299–308. doi:10.1017/S0033291707002346. PMC 2914546. PMID 18680625.
  35. ^ Rivenson, Abraham; Hoffmann, Dietrich; Prokopczyk, Bogdan; Amin, Shantu; Hecht, Stephen S. (1988-12-01). "Induction of Lung and Exocrine Pancreas Tumors in F344 Rats by Tobacco-specific and Areca-derived N-Nitrosamines". Cancer Research. 48 (23): 6912–7. PMID 3180100. Archived from the original on 2012-07-09. Retrieved 2009-02-27.
  36. ^ Fesinmeye, Megan Dann (July 14, 2006). Smokeless Tobacco, Swedish Snus, and Pancreatic Cancer. The 13th World Conference on Tobacco and Health Conference. Washington, DC. Archived from the original on December 7, 2008. Retrieved June 13, 2006.
  37. ^ Luo, Juhua; Ye, Weimin; Zendehdel, Kazem; Adami, Johanna; Adami, Hans-Olov; Boffetta, Paolo; Nyrén, Olof (2007). "Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: A retrospective cohort study". The Lancet. 369 (9578): 2015–20. doi:10.1016/S0140-6736(07)60678-3. hdl:11585/682489. PMID 17498797. S2CID 6676039.
  38. ^ "Use Of Swedish 'Snus' Is Linked To A Doubled Risk Of Pancreatic Cancer". Science Daily. May 11, 2007. Archived from the original on November 16, 2018. Retrieved February 28, 2018.
  39. ^ "Swedish Snus Much Safer Than Smoking But Linked To Pancreatic Cancer". Medical News Today. 10 May 2007. Archived from the original on 23 February 2008. Retrieved 14 June 2008.
  40. ^ "Snus och blodtryck" [Snuff and blood pressure] (in Swedish). Läkartidningen. November 21, 2008. Archived from the original on March 10, 2014. Retrieved May 3, 2012.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Health_effects_of_snus&oldid=1243690728"